<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-2466-3-1.anc" start="11549" end="11555" sStart="11462" offset="87" sid="r11.severe.j.0386" wn="1" wnkey="severe%5:00:00:intense:00" annotator="anfahmy" text="Most previous reports of HTLV-I bronchio-alveolitis reported more frequent and severe pathological and biological abnormalities of bronchoalveolar lavage fluid in patients with HTLV myelopathy or uveitis compared to HTLV-I carriers without apparent disease [ 6 8 14 ] . Since our patients were without overt inflammatory disease, we cannot comment on potential pulmonary function abnormalities in patients with clinical inflammation." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2466-3-1.anc" start="6565" end="6571" sStart="null" offset="19" sid="r8.number.n.0904" wn="1" wnkey="number%1:07:00::" annotator="cgozo" text="Due to the limited number of subjects, we were unable to stratify the analysis by center." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2466-3-1.anc" start="508" end="514" sStart="null" offset="47" sid="r9.level.n.0201" wn="1" wnkey="level%1:07:00::" annotator="veweser" text="Biological studies have demonstrated increased levels of CD3+/CD25+ lymphocytes [ 5 ] , HTLV-I proviral load and HTLV-I tax/rex mRNA expression [ 6 7 ] , HTLV-I specific IgA [ 8 ] , soluble interleukin-2 receptors [ 9 ] , beta-chemokines [ 7 ] and soluble intracellular adhesion molecule-1 (ICAM-1) [ 10 ] , in bronchoalveolar lavage fluid from HTLV-I infected humans." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2466-3-1.anc" start="1384" end="1392" sStart="null" offset="60" sid="r11.function.n.0935" wn="2" wnkey="function%1:07:00::" annotator="anfahmy" text="However, whether HTLV-I or HTLV-II alters pulmonary function is unknown." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2466-3-1.anc" start="10050" end="10059" sStart="null" offset="230" sid="r8.1.different.j.0612" wn="1" wnkey="different%3:00:00::" annotator="cgozo" text="The results of the multivariable linear regression analysis are presented in Table 2. For both FVC and FEV1 adjusted for height squared, mean values were only minimally smaller for the HTLV-I group, and no different at all for the HTLV-II group, both compared to HTLV seronegatives." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2466-3-1.anc" start="6745" end="6749" sStart="null" offset="89" sid="r11.able.j.0599" wn="1" wnkey="able%3:00:00::" annotator="anfahmy" text="Power calculations revealed that, relative to the seronegatives, the study was able to detect a 10 percent decrease in the parameters measured with power (1 - beta) of 0.65 to 0.85 for HTLV-I and 0.82 to 0.96 for HTLV-II." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2466-3-1.anc" start="13762" end="13766" sStart="null" offset="70" sid="r11.able.j.0921" wn="1" wnkey="able%3:00:00::" annotator="adelpriore" text="Due to information gathered in the cohort study, we were also able to control for other potential confounding variables such as cigarette smoking and alcohol intake." />
  </sentences>
</list>